CTLA4 and renal cell adenocarcinoma: Despite the relatively high rates of response to combinations of PD-1 and/or CTLA-4 axis inhibition in RCC that form the new standard-of-care, most patients with RCC do not receive durable clinical benefit from these therapies (7).